View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 28, 2016

M&As this week: Johnson & Johnson, DNA2.0

Johnson & Johnson has announced its plans to acquire Neostrata, its affiliates and Tristrata Incorporated.

Johnson & Johnson

Johnson & Johnson has announced its plans to acquire Neostrata, its affiliates and Tristrata Incorporated.

The acquisition enables Johnson & Johnson and Neostrata to discover and develop new important skincare solutions associated with human insights and compelling science.

DNA2.0 has announced its plans to develop protein pharmaceutical research by employing unparalleled antibody production and engineering platform through acquisition of MIGS’s assets.

Pursuant to the transaction, Michael Feldhaus, the co-founder of MIGS, will join DNA2.0 team as senior vice-president of antibody technologies in Newark, California.


Image: Johnson & Johnson has announced its plans to acquire Neostrata; Photo: courtesy of Luis Gracia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology